On a form 8-k filed with the US Securities and Exchange Commission (SEC), United Therapeutics reported the following: “On September 20, 2022, United Therapeutics Corporation (the Company) announced the termination of the PERFECT clinical study evaluating Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease. The Company terminated the study based upon a recommendation of the study’s independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC. The Company will review the available data from the study and plans to share the results with the scientific community.”
The PERFECT trial was initiated in 2018 and was expected to enroll 314 subjects.
View the United Therapeutics Form 8-k.
